Preclinical Showcase of XmAb541 in Claudin 6-Targeted Bispecific Antibody Therapy
Time: 9:30 am
day: Conference Day 1
Details:
• Showcasing Xencor’s XmAb541, a CLDN6 x CD3 bispecific antibody, designed to engage T cells and selectively kill claudin 6 expressing tumor cells while sparing normal tissues
• Uncovering preclinical data, focusing on safety, tolerability, and preliminary efficacy against ovarian cancer and other solid tumors
• Outlining future development plans, including combination strategies with other immunotherapies and expansion into additional CLDN6-positive cancer types
